Display options
Cite
Usman MH, Notaro LA, Patel H, et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008;10(5):388-97doi: 10.1007/s11936-008-0030-0.
Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current treatment options in cardiovascular medicine, 10(5), 388-97. https://doi.org/10.1007/s11936-008-0030-0
Usman, M Haris U, et al. "New developments in anticoagulation for atrial fibrillation." Current treatment options in cardiovascular medicine vol. 10,5 (2008): 388-97. doi: https://doi.org/10.1007/s11936-008-0030-0
Usman MH, Notaro LA, Patel H, Ezekowitz MD. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0. PMID: 18814828.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0.

New developments in anticoagulation for atrial fibrillation.

Current treatment options in cardiovascular medicine

M Haris U Usman, Lawrence A Notaro, Harsh Patel, Michael D Ezekowitz

Affiliations

  1. Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.

PMID: 18814828 DOI: 10.1007/s11936-008-0030-0

Abstract

The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this indication. However, despite its efficacy, warfarin management is tedious and is useful only in a subsegment of the population who needs anticoagulation and has no contraindications. Many agents are poised to replace warfarin as an effective anticoagulant for stroke prevention in AF. The direct thrombin inhibitor dabigatran is furthest along in clinical development, followed by the factor Xa inhibitors rivaroxaban and apixaban. All these agents seem effective, and none appears mechanistically superior over another. Dabigatran's advantage is that it was tested in two dosages in a phase 3 evaluation based on earlier phase 2 studies in patients with AF, whereas dosage data for the other agents were extrapolated from phase 2 programs for venous thromboembolism prevention. The vitamin K antagonist ATI-5923 offers clinical benefits similar to warfarin's, but with no or fewer drug-drug interactions, potentially greater time in therapeutic range, and probably less need for dose adjustment and laboratory monitoring. It challenges the newer mechanistic agents in efficacy and raises the bar for comparison in future head-to-head trials. Further analysis and clinical trial testing are still needed to determine whether one or all of these agents are effective anticoagulants for stroke prevention in patients with AF.

References

  1. J Thromb Thrombolysis. 2006 Dec;22(3):191-7 - PubMed
  2. J Thromb Haemost. 2007 Dec;5(12):2368-75 - PubMed
  3. Circulation. 2006 Dec 5;114(23):2490-7 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1895-900 - PubMed
  5. Ann Intern Med. 2007 Jun 19;146(12):857-67 - PubMed
  6. Thromb Res. 2003;112(3):167-74 - PubMed
  7. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):129-39 - PubMed
  8. J Invasive Cardiol. 2000 Dec;12 Suppl F:27F-32 - PubMed
  9. J Am Coll Cardiol. 2005 Dec 6;46(11):1986-95 - PubMed
  10. Curr Opin Investig Drugs. 2002 Jun;3(6):905-7 - PubMed
  11. Thromb Haemost. 2007 Oct;98(4):883-8 - PubMed
  12. Circulation. 2006 Jul 11;114(2):119-25 - PubMed
  13. Int J Clin Pharmacol Ther. 2007 Jun;45(6):335-44 - PubMed
  14. Eur J Clin Pharmacol. 2005 Dec;61(12):873-80 - PubMed
  15. JAMA. 2005 Feb 9;293(6):690-8 - PubMed
  16. Am J Cardiol. 2007 Nov 1;100(9):1419-26 - PubMed
  17. J Intern Med. 2003 Oct;254(4):335-42 - PubMed
  18. J Thromb Thrombolysis. 2006 Feb;21(1):67-72 - PubMed
  19. J Biol Chem. 1989 Nov 25;264(33):20012-6 - PubMed
  20. Circulation. 2001 Jul 3;104(1):74-8 - PubMed
  21. Circulation. 1998 Feb 17;97(6):544-52 - PubMed
  22. Blood. 2000 Nov 15;96(10):3459-65 - PubMed
  23. Circ Res. 1994 Jan;74(1):56-63 - PubMed
  24. J Thromb Haemost. 2008 Mar;6(3):457-63 - PubMed
  25. J Biol Chem. 1991 Jun 15;266(17):11317-27 - PubMed
  26. J Thromb Haemost. 2005 Mar;3(3):514-21 - PubMed
  27. Lancet. 2007 Aug 11;370(9586):493-503 - PubMed
  28. J Am Coll Cardiol. 2007 Jun 26;49(25):2398-407 - PubMed
  29. J Thromb Haemost. 2007 Apr;5(4):746-53 - PubMed
  30. J Thromb Haemost. 2007 Aug;5(8):1660-5 - PubMed
  31. Lancet. 2003 Nov 22;362(9397):1691-8 - PubMed
  32. Circulation. 1996 May 15;93(10):1913-8 - PubMed
  33. J Med Chem. 2007 Nov 1;50(22):5339-56 - PubMed
  34. N Engl J Med. 1982 Apr 29;306(17):1018-22 - PubMed
  35. J Clin Pharmacol. 2006 May;46(5):549-58 - PubMed
  36. Clin Pharmacol Ther. 2002 Apr;71(4):235-45 - PubMed
  37. Lancet. 2006 Jun 10;367 (9526):1903-12 - PubMed
  38. Thromb Haemost. 1997 Sep;78(3):1142-9 - PubMed
  39. J Clin Pharmacol. 2007 Feb;47(2):218-26 - PubMed
  40. Arch Intern Med. 2000 Jan 10;160(1):41-6 - PubMed

Publication Types